Skip to main content
Category

Research

MEDPAGE TODAY
ResearchTreatments

Drug Active in ‘Undruggable’ KRAS-Mutant NSCLC

*September 2020* A small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients with non-small cell lung cancer (NSCLC). A third of patients with NSCLC had objective responses with sotorasib, and 88.1% attained disease control. The disease control rate (DCR) surpassed 90% in…
laurabbook@gmail.com
October 16, 2020
Onc Live
ResearchTreatments

BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models

*September 2020* Additionally, the findings showed that BLU-945 potently and selectively inhibited triple-mutant EGFR, harboring the most common on-target resistance mutations to standard EGFR-targeted therapies, including the third-generation EGFR TKI osimertinib (Tagrisso). Specifically, BLU-945 inhibited triple-mutant EGFR with sub-nanomolar potency and it also showed a greater than 900-fold selectivity over…
laurabbook@gmail.com
October 16, 2020
Onc Live
ResearchTreatments

EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC

*September 2020* The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib (Tagrisso)-resistant patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to findings from the phase 1 CHRYSALIS study that were presented during the 2020 ESMO Virtual Congress.…
laurabbook@gmail.com
October 16, 2020